TGFB1 and chronic kidney disease: In CKD, Aldo acts on infiltrating inflammatory cells; inducing ROS production; stimulating epidermal growth factor receptor and AT1 expression; activating transcription factors NFκB and activating protein-1; increasing the release of proinflammatory cytokine TNFα and chemokines CCL2 and CCL5; and promoting TGFβ1 and PAI-1 production [66,67].